Zacks: Analysts Set $30.50 Price Target for Regenxbio Inc. (RGNX)
Shares of Regenxbio Inc. (NASDAQ:RGNX) have earned a consensus broker rating score of 1.13 (Strong Buy) from the four analysts that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company.
Analysts have set a 1 year consensus price objective of $30.50 for the company and are expecting that the company will post ($0.60) earnings per share for the current quarter, according to Zacks. Zacks has also given Regenxbio an industry rank of 111 out of 265 based on the ratings given to its competitors.
A number of research analysts recently weighed in on RGNX shares. Zacks Investment Research upgraded shares of Regenxbio from a “hold” rating to a “buy” rating and set a $8.75 price objective for the company in a report on Wednesday, July 6th. Piper Jaffray Cos. reiterated a “buy” rating and issued a $33.00 price target on shares of Regenxbio in a research note on Tuesday, July 5th. Finally, Chardan Capital reiterated a “buy” rating on shares of Regenxbio in a research note on Monday, August 22nd.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/14/zacks-analysts-set-30-50-price-target-for-regenxbio-inc-rgnx.html
Shares of Regenxbio (NASDAQ:RGNX) traded down 2.99% on Friday, reaching $16.25. 65,086 shares of the company’s stock were exchanged. The firm’s market capitalization is $430.06 million. Regenxbio has a one year low of $7.07 and a one year high of $25.00. The firm has a 50 day moving average of $14.26 and a 200 day moving average of $11.36.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by $0.02. Regenxbio had a negative net margin of 451.73% and a negative return on equity of 17.89%. On average, equities research analysts predict that Regenxbio will post ($2.37) EPS for the current year.
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Nationwide Fund Advisors increased its position in shares of Regenxbio by 196.1% in the second quarter. Nationwide Fund Advisors now owns 12,815 shares of the company’s stock worth $103,000 after buying an additional 8,487 shares in the last quarter. Metropolitan Life Insurance Co. NY bought a new stake in shares of Regenxbio during the second quarter valued at $136,000. Rhumbline Advisers bought a new stake in shares of Regenxbio during the second quarter valued at $148,000. A.R.T. Advisors LLC bought a new stake in shares of Regenxbio during the second quarter valued at $220,000. Finally, Strs Ohio increased its stake in shares of Regenxbio by 19.6% in the second quarter. Strs Ohio now owns 29,600 shares of the company’s stock valued at $236,000 after buying an additional 4,859 shares in the last quarter. Institutional investors own 68.73% of the company’s stock.
Regenxbio Company Profile
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regenxbio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.